Soligenix, Inc. (SNGX)

Over the past year, Soligenix's stock has experienced a significant decline. In September 2025, Soligenix announced the pricing of a public offering of common stock and warrants, aiming to raise approximately $7.5 million. In November 2025, the company announced its third-quarter 2025 financial results, reporting no revenue and a net loss of $2.5 million, and stated it had approximately $10.5 million in cash as of September 30, 2025. The stock price fluctuated in December 2025 and January 2026. In February 2026, a buy signal was issued from a pivot bottom point, and the stock subsequently rose, but also holds sell signals from both short and long-term Moving Averages.

There is no explicit mention of demand seasonality for Soligenix, Inc.'s products and services. Demand is likely driven by factors such as disease prevalence, the progression and success of clinical trials, regulatory approvals, government funding for public health initiatives, and the emergence of infectious disease threats, rather than typical seasonal consumer patterns.

Soligenix, Inc. is a late-stage biopharmaceutical company based in the United States, focused on developing and commercializing products to treat rare diseases with unmet medical needs. The company operates within the manufacturing sector, specifically in the pharmaceutical preparation industry. The company's business is divided into two primary segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment focuses on therapies for oncology, inflammatory, and immune-mediated conditions, including HyBryte™ for CTCL, SGX302 for psoriasis, Dusquetide for oral mucositis, and SGX945 for Behçet's Disease. The Public Health Solutions segment includes development programs for vaccines and treatments addressing biodefense-related infectious disease threats and broader public health challenges, including RiVax®, SGX943, Filovirus vaccines, CiVax™, and ThermoVax®.

Soligenix, Inc. is based in the United States, with its headquarters in Princeton, NJ. The company is pursuing worldwide regulatory approvals for its product candidates, such as HyBryte™ for CTCL.

Soligenix's brand reputation is shaped by its efforts in developing treatments for rare diseases and public health solutions. The company is recognized for its focus on addressing unmet medical needs and advancing innovative therapies. Positive developments include the successful transfer of synthetic hypericin manufacturing, positive data for extended HyBryte, promising Phase 2a results for SGX945, publication describing preclinical efficacy of CiVax, and the DMC meeting concluding no safety concerns for HyBryte™.

The ownership structure of Soligenix stock is a mix of institutional, retail, and individual investors. Approximately 11.37% of the company's stock is owned by Institutional Investors, 3.86% by Insiders, and 84.77% by Public Companies and Individual Investors. Major institutional shareholders include Armistice Capital, Llc, DRW Securities, LLC, and Two Sigma Investments, Lp.